HCAR2 Human Gene Knockout Kit (CRISPR)

CAT#: KN206527RB

HCAR2 - human gene knockout kit via CRISPR, HDR mediated

Product Images

Specifications

Product Data

• Format: 2 gRNA vectors, 1 RFP-BSD donor, 1 scramble control
• Donor DNA: RFP-BSD
• Symbol: HCAR2
• Locus ID: 338442
• Components:

  KN206527G1, HCAR2 gRNA vector 1 in pCas-Guide CRISPR vector

  KN206527G2, HCAR2 gRNA vector 2 in pCas-Guide CRISPR vector

  KN206527RBD, donor DNA containing left and right homologous arms and RFP-BSD functional cassette.

  GE100003, scramble sequence in pCas-Guide vector

• Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

Reference Data

• RefSeq: NM_177551
• UniProt ID: Q8TDS4
• Synonyms: GPR109A; HCA2; HM74a; HM74b; NIACR1; Puma-g; PUMAG
• Summary: Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.[UniProtKB/Swiss-Prot Function]